眾生藥業(002317.SZ):先強藥業的普拉洛芬原料藥獲得日本醫藥品適合性調查結果通知書
格隆匯2月7日丨眾生藥業(002317.SZ)公佈,公司全資子公司廣東先強藥業有限公司(簡稱“先強藥業”)於近日收到日本獨立行政法人醫藥品醫療器械綜合機構簽發的普拉洛芬原料藥《醫藥品適合性調查結果通知書》。
普拉洛芬屬於丙酸類非甾體抗炎藥,其作用機制為主要抑制環氧合酶(COX)活性,阻斷二十碳四烯酸衍生物的合成,抑制前列腺素的合成,緩解炎症反應。普拉洛芬滴眼液適應症為外眼及眼前節炎症的對症治療(眼瞼炎、結膜炎、角膜炎、鞏膜炎、淺層鞏膜炎、虹膜睫狀體炎、術後炎症)。
米內網中國城市公立醫院和城市藥店化學藥終端競爭格局數據庫顯示,普拉洛芬滴眼液2021至2023年日本千壽製藥年銷售額分別為人民幣34,746.00萬元,31,431.00萬元,39,765.00萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.